We are international

The International Myeloma Working Group, a collaborative group of leading myeloma specialists around the globe, has a two-fold task: to publish consensus statements and guidelines for the management of myeloma and to conduct translational research—from lab bench to patient bedside--under the auspices of the International Myeloma Foundation. The following publications represent the work of individual IMWG members who have based their papers on IMWG data sets that were made available to them.

A Practical Guide to Achieving and Maintaining the Best Response to Lenalidomide in Multiple Myeloma: Roundtable Proceedings
Clinical Advances in Hematology & Oncology Vol 5, 10, Suppl 15, 2007

Clinically relevant end points and new drug approvals for myeloma
Leukemia, 2008

Confirmation of the utility of the International Staging System and identification of a unique pattern of disease in Brazilian patients with multiple myeloma
Haematologica, 2008, Vol 93, Issue 5, 791-792

Eliminating the complete response penalty from myeloma response criteria
Blood, 2008, 5759-5760

ESAs not the culprit: More studies required
American Journal of Hematology, 2008

Genetic association with thalidomide mediated venous thrombotic events in myeloma indentified using targeted genotyping
Blood, 2008

Genetic Factors Underlying the Risk of Thalidomide-Related Neuropathy in Patients with Multiple Myeloma
Johnson D, et al.
J Clin Oncol. 2011 Mar 1;29(7):797-804

Genetic polymorphisms of EPHX1, Gsk3 beta, TNFSF8 and myeloma cell DKK-1 expression linked to bone disease in myeloma
Leukemia, 2009

Genetic Predisposition for Chemotherapy-induced Neuropathy in Multiple Myeloma
Becker P, et al.
J Clin Oncol. 2011 Mar 1;29(7):783-6

Genomic variation in myeloma: design, content, and initial application of the Bank on a Cure SNP Panel to detect associations with progression-free survival
Van Ness B, et al.
BMC Med. 2008 Sep 8;6:26

Long-Term Follow-Up of Autotransplantation Trials for Multiple Myeloma: Update of Protocols Conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences
Journal of Clinical Oncology, 2010

Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial
Broyl A, et al.
Lancet Oncol. 2010 Nov;11(11):1057-65

Myeloma Minute
December 5, 2013

New Approaches to Treatment for Multiple Myeloma: Durable Remission and Quality of Life as Primary Goals
Clinical Lymphoma & Myeloma, Vol 6 No 3, 181-190, 2005

Oncology Nurses Take the Lead in Providing Novel Therapy Guidelines for Multiple Myeloma
Clinical Journal of Oncology Nursing, 2008, 7-8, Vol 12, Issue 3

Osteonecrosis of the Jaw and Biphosphonates
New England Journal of Medicine 2005

RT-PCR Amplicons in the Plasma of Multiple Myeloma Patients
Acta Oncologica Vol. 39, No. 7, pp. 789-796, 2000

Survival and Years of Life Lost in Different Age Cohorts of Patients With Multiple Myeloma
Journal of Clinical Oncology, 2010

Use of Bisphosphonates in Multiple Myeloma: IMGW Response to Mayo Clinic Consensus Statement
Mayo Clinic Proceedings Vol 82, 4, 516-522, 2007